CompletedNot Applicable

Patient-Centric Innovation: Superior Vena Cava Approach in Zero-Fluoroscopy

China31 participantsStarted 2022-10-01

Plain-language summary

This study aims to evaluate the viability and therapeutic efficacy of zero-fluoroscopy radiofrequency catheter ablation (RFCA) using the superior vena cava (SVC) approach in patients with atrioventricular nodal reentrant tachycardia (AVNRT). The study compares outcomes between the SVC approach and the conventional inferior vena cava (IVC) approach. Patients diagnosed with AVNRT who underwent RFCA between June 2022 and October 2022 were retrospectively analyzed. The primary outcome measure is the non-inducibility of AVNRT, while secondary outcomes include postoperative recovery time and complication rates. The study seeks to provide a safer and more efficient RFCA method, enhancing patient recovery by minimizing radiation exposure and optimizing catheter access routes.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged \>18 years. * Diagnosed with atrioventricular nodal reentrant tachycardia (AVNRT). * Underwent radiofrequency catheter ablation (RFCA) at our institution between June 2022 and October 2022. * Experienced at least one episode of AVNRT during transesophageal atrial pacing (TEAP) and programmed stimulation. * Provided informed consent for the procedure and data collection. Exclusion Criteria: * AVNRT attributed to reversible causes, such as acute myocarditis or recent cardiac surgery. * Presence of other types of tachycardias (e.g., atrial tachycardia, Wolff-Parkinson-White syndrome, ventricular tachycardia). * Inability to abstain from pharmacological interventions for at least five half-lives of the medication prior to TEAP. * Contraindications for the use of conscious sedation or local anesthesia. * Severe comorbidities that would interfere with study participation or follow-up. * Patients who are pregnant or lactating. * Previous RFCA procedures for AVNRT within the past six months.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Non-inducibility of Atrioventricular Nodal Reentrant Tachycardia (AVNRT)

Timeframe: During the procedure

Recurrence of supraventricular tachycardia

Timeframe: Within 1 year post-procedure

Trial details

NCT IDNCT06492499

SponsorNing Zhou

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-10-01

View on ClinicalTrials.gov More Atrioventricular Nodal Reentrant Tachycardia trials